Diagnostic value and prognostic significance of LI‑cadherin and miR‑378e in colorectal cancer

Wang,Xujie; Li,Zhihua; Fu,Jixin; Xu,Weiwei; Li,Zongxian

doi:10.3892/ol.2020.11755

Diagnostic value and prognostic significance of LI‑cadherin and miR‑378e in colorectal cancer

Authors:
- Xujie Wang
- Zhihua Li
- Jixin Fu
- Weiwei Xu
- Zongxian Li
View Affiliations

Affiliations: Department I of Gastrointestinal Surgery, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China, Department Ⅲ of Oncology, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China, Department Ⅱ of Gastrointestinal Surgery, Weihai Central Hospital, Weihai, Shandong 264400, P.R. China
Published online on: June 19, 2020 https://doi.org/10.3892/ol.2020.11755
Pages: 2456-2464
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression levels of LI‑cadherin and miR‑378e in the serum of patients with colorectal cancer, and the diagnostic value and prognostic significance in colorectal cancer were investigated. A total of 110 patients who were diagnosed with colorectal cancer in Weihai Central Hospital, from January 2012 to November 2014, were selected and enrolled in the experimental group, and 90 healthy subjects who underwent physical examination were enrolled in the control group. The expression level of miR‑378e in serum was detected by reverse transcription‑quantitative PCR and the expression of LI‑cadherin in serum was detected by ELISA. ROC curves of LI‑cadherin and miR‑378e were drawn and the sensitivity and specificity of the diagnosis were estimated. The association of the expression levels of LI‑cadherin and miR‑378e with the survival of the patients was analyzed. LI‑cadherin and miR‑378e expression levels were significantly higher in the control group than those in the experimental group (P<0.001). LI‑cadherin was significantly associated with the pathogenic site, the lymphatic metastasis, depth of infiltration, degree of differentiation and clinical stage (P<0.05). The sensitivity and specificity of the LI‑cadherin combined with miR‑378e detection were respectively 86 and 94%; the sensitivity of miR‑378e detection was the highest, as well as the specificity of the combined detection. At the end of the follow‑up period, the survival rates of the patients in the LI‑cadherin high‑expression group and miR‑378e high‑expression group were significantly higher than those in the low‑expression groups (P<0.05). There was a significant positive correlation between the LI‑cadherin and miR‑378e expression levels in both the experimental and control group (r=0.5845 and 0.6356, respectively; P<0.05). In conclusion, LI‑cadherin and miR‑378e are expressed at low levels in colorectal cancer, suggesting that they have a good diagnostic value for colorectal cancer and can be used as biomarkers for colorectal cancer prognosis.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kwon CH, Park HJ, Choi JH, Lee JR, Kim HK, Jo HJ, Kim HS, Oh N, Song GA and Park DY: Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer. Oncotarget. 6:20312–20326. 2015. View Article : Google Scholar : PubMed/NCBI
3	Koerner J, Brunner T and Groettrup M: Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice. Oncotarget. 8:50873–50888. 2017. View Article : Google Scholar : PubMed/NCBI
4	Sun X, Wang T, Zhang C, Ning K, Guan ZR, Chen SX, Hong TT and Hua D: S100A16 is a prognostic marker for colorectal cancer. J Surg Oncol. 117:275–283. 2018. View Article : Google Scholar : PubMed/NCBI
5	Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, et al: Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 116:544–573. 2010. View Article : Google Scholar : PubMed/NCBI
6	Bagaria B, Sood S, Sharma R and Lalwani S: Comparative study of CEA and CA19-9 in esophageal, gastric and colon cancers individually and in combination (ROC curve analysis). Cancer Biol Med. 10:148–157. 2013.PubMed/NCBI
7	Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E and Tekkis PP: Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol. 18:15–24. 2009. View Article : Google Scholar : PubMed/NCBI
8	Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, et al: Free DNA and carcinoembryonic antigen serum levels: An important combination for diagnosis of colorectal cancer. Clin Cancer Res. 12:6985–6988. 2006. View Article : Google Scholar : PubMed/NCBI
9	Bartolmäs T, Hirschfeld-Ihlow C, Jonas S, Schaefer M and Gessner R: LI-cadherin cis-dimerizes in the plasma membrane Ca (2+) independently and forms highly dynamic trans-contacts. Cell Mol Life Sci. 69:3851–3862. 2012. View Article : Google Scholar : PubMed/NCBI
10	Gessner R and Tauber R: Intestinal cell adhesion molecules. Liver-intestine cadherin. Ann N Y Acad Sci. 915:136–143. 2000. View Article : Google Scholar : PubMed/NCBI
11	Ordóñez NG: Cadherin 17 is a novel diagnostic marker for adenocarcinomas of the digestive system. Adv Anat Pathol. 21:131–137. 2014. View Article : Google Scholar : PubMed/NCBI
12	Snow AN, Mangray S, Lu S, Clubwala R, Li J, Resnick MB and Yakirevich E: Expression of cadherin 17 in well-differentiated neuroendocrine tumours. Histopathology. 66:1010–1021. 2015. View Article : Google Scholar : PubMed/NCBI
13	Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, Sun Q, Yan F, Yan C, Li H, et al: The hOGG1 Ser326Cys polymorphism contributes to digestive system cancer susceptibility: Evidence from 48 case-control studies. Tumour Biol. 36:1029–1038. 2015. View Article : Google Scholar : PubMed/NCBI
14	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
15	Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez- Dorantes M and Hidalgo-Miranda A: miRNA biogenesis: Biological impact in the development of cancer. Cancer Biol Ther. 15:1444–1455. 2014. View Article : Google Scholar : PubMed/NCBI
16	Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
17	Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ and Schmittgen TD: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 120:1046–1054. 2007. View Article : Google Scholar : PubMed/NCBI
18	Magrelli A, Azzalin G, Salvatore M, Viganotti M, Tosto F, Colombo T, Devito R, Di Masi A, Antoccia A, Lorenzetti S, et al: Altered microRNA expression patterns in hepatoblastoma patients. Transl Oncol. 2:157–163. 2009. View Article : Google Scholar : PubMed/NCBI
19	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
20	Gao L, Tian Y, Zhao Z, Zhang L, He X and Pei Y: Expression and clinical significance of miR-224 and miR-378e in colorectal cancer tissues. Tianjin Med J. 8:737–739, 20113.
21	Tang R, Liang L, Luo D, Feng Z, Huang Q, He R, Gan T, Yang L and Chen G: Downregulation of miR-30a is associated with poor prognosis in lung cancer. Med Sci Monit. 21:2514–2520. 2015. View Article : Google Scholar : PubMed/NCBI
22	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
23	Alnabulsi A and Murray GI: Integrative analysis of the colorectal cancer proteome: Potential clinical impact. Expert Rev Proteomics. 13:917–927. 2016. View Article : Google Scholar : PubMed/NCBI
24	Chen Z, Gao S, Wang D, Song D and Feng Y: Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody through adapted autophagy. Am J Transl Res. 8:1190–1196. 2016.PubMed/NCBI
25	Dimofte G, Târcoveanu E, Taraşi M, Panait C, Lozneanu G, Nicolescu S, Porumb V and Grigoraş O: Mean number of lymph nodes in colonic cancer specimen: Possible quality control index for surgical performance. Chirurgia (Bucur). 106:759–764. 2011.PubMed/NCBI
26	Stojkovic Lalosevic M, Stankovic S, Stojkovic M, Markovic V, Dimitrijevic I, Lalosevic J, Petrovic J, Brankovic M, Pavlovic Markovic A and Krivokapic Z: Can preoperative CEA and CA19-9 serum concentrations suggest metastatic disease in colorectal cancer patients? Hell J Nucl Med. 20:41–45. 2017.PubMed/NCBI
27	Li R, Yang HQ, Xi HL, Feng S and Qin RH: Inhibition of CDH17 gene expression via RNA interference reduces proliferation and apoptosis of human MKN28 gastric cancer cells. Int J Oncol. 50:15–22. 2017. View Article : Google Scholar : PubMed/NCBI
28	Yu Q, Shen W, Zhou H, Dong W and Gao D: Knockdown of LI-cadherin alters expression of matrix metalloproteinase-2 and −9 and galectin-3. Mol Med Rep. 13:4469–4474. 2016. View Article : Google Scholar : PubMed/NCBI
29	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
30	Bernhard OK, Greening DW, Barnes TW, Ji H and Simpson RJ: Detection of cadherin-17 in human colon cancer LIM1215 cell secretome and tumour xenograft-derived interstitial fluid and plasma. Biochim Biophys Acta. 1834:2372–2379. 2013. View Article : Google Scholar : PubMed/NCBI
31	van der Wurff AA, Vermeulen SJ, van der Linden EP, Mareel MM, Bosman FT and Arends JW: Patterns of alpha- and beta-catenin and E-cadherin expression in colorectal adenomas and carcinomas. J Pathol. 182:325–330. 1997. View Article : Google Scholar
32	Takamura M, Ichida T, Matsuda Y, Kobayashi M, Yamagiwa S, Genda T, Shioji K, Hashimoto S, Nomoto M, Hatakeyama K, et al: Reduced expression of liver-intestine cadherin is associated with progression and lymph node metastasis of human colorectal carcinoma. Cancer Lett. 212:253–259. 2004. View Article : Google Scholar : PubMed/NCBI
33	Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, Russo V, Affinito A, Puoti I, Quintavalle C, et al: Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget. 8:19592–19608. 2017. View Article : Google Scholar : PubMed/NCBI